All Stories

  1. Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry
  2. Hepatic Metabolic Dysregulation as a Potential Amplifier of Leukemogenesis Following mRNA Vaccination: A Novel Mechanistic Hypothesis
  3. Comparison of Efficiency and Side Effects of Daily and Alternate Day Oral Iron
  4. Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874
  5. A Signet Ring Cell Carcinoma Presented as Refractory Acquired Thrombotic Thrombocytopenic Purpura
  6. A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis
  7. In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus
  8. Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
  9. Splenic Marginal Zone Lymphoma in Turkey: Association With Hepatitis B Instead Of Hepatitis C Virus As An Etiologic and Possible Prognostic Factor-Multicenter Cohort Study
  10. The factors affecting early death in newly diagnosed APL patients
  11. The impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of patients with acute myeloid leukemia
  12. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
  13. Indications and outcomes of splenectomy for hematological disorders
  14. The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia
  15. Fibrosis Development, Leukemic Transformation and Secondary Malignancies Complicating the Clinical Course of Essential Thrombocythemia
  16. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia
  17. Pediatric Chemotherapeutic Regimen (BFM-95) is Superior for Overall Survival in Adult Acute Lymphoblastic Leukemia
  18. Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
  19. Combination of novoseven and feiba in hemophiliac patients with inhibitors
  20. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients
  21. Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
  22. Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors
  23. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis
  24. Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission
  25. Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines
  26. Experience with Pegylated Interferon α-2a in 30 Patients Diagnosed with Hematologic Neoplasms
  27. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma
  28. The Prognosis of Adult Burkitt’s Cell Leukemia in Real-Life Clinical Practice
  29. Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level
  30. Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis
  31. The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases.
  32. Poster Session TPS 1-18
  33. Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders.
  34. Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case
  35. The Impact of Iron Overload on Transplant-Related Complications and Prognosis of Acute Leukemias.
  36. Reply
  37. Chimeric antigen receptor T cell treatment in hematologic malignancies
  38. Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids
  39. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML.
  40. Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers
  41. Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factors.
  42. Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib
  43. Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission
  44. Erdheim-Chester Disease: A Case Report
  45. Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
  46. Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
  47. Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case
  48. Giant Hemophilic Pseudotumor of the Iliopsoas: Case Report
  49. Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management
  50. Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models
  51. Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete Remission
  52. PP-025 ADVANCED PHASE CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB, NILOTINIB, DASATINIB AND INTERFERON WITHOUT ABL KINASE MUTATION
  53. PP-020 AN ESSENTIAL THROMBOCYTOSIS CASE, WHICH TRANSFORMED TO ACUTE MYELOID LEUKEMIA AFTER 12 YEARS
  54. PP-021 ASHERMAN SYNDROME WITH FACTOR 7 DEFICIENCY: CASE REPORT
  55. PP-058 MYASTENIA GRAVIS AND WALDENSTROM MACROGLOBULINEMIA: IS COMMON IMMUNOLOGIC MECHANISM POSSIBLE?
  56. PP-063 TWO CASES WITH PRIMARY IMMUNE DEFICIENCY AND NEOPLASTIC LYMPHOID PROLIFERATION